The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.

Abstract 2923 Poster Board II-899 Background: MCL is characterized by the presence of the t(11;14) translocation that juxtaposes the cyclin D1 gene downstream of the immunoglobulin heavy-chain gene promoter resulting in enhanced G1μS phase transition leading to cellular proliferation. Despite the common genetic lesion, patients exhibit considerable heterogeneity in their clinical behavior and response to therapy. The clinical significance of the microenvironment in follicular lymphoma has been highlighted by gene expression studies demonstrating that a T-cell response signature correlates with a superior outcome compared to that seen with a macrophage signature. In contrast, the significance of the non-malignant cellular component in MCL biopsies remains unknown. We report the results of a retrospective study examining flow cytometry (FCM) of MCL diagnostic tissue biopsies, focusing on the non-malignant lymphoid cells. Method: Patients were included in the study if they had MCL diagnosed according to the 2008 WHO criteria, had FCM performed on their diagnostic nodal or tissue biopsy and had adequate clinical information that included baseline clinical characteristics, treatment regimens and clinical outcome. Patients were excluded if they were too frail to receive chemotherapy or if FCM was only performed on peripheral blood or bone marrow. 122 patients met the criteria for inclusion in the study; of which 56 were also assessable by tissue microarray (TMA). FCM data were re-analyzed for expression of CD3, CD4, CD8, CD19, CD20 and kappa and lambda light chains on cells gating on lymphoid populations. Estimates of the non-neoplastic B-cells were derived from total CD19/CD20 positive B cells excluding the light chain restricted population. ‘High9 and ‘low9 expressers for each marker were determined by examining frequency histograms for a trough. TMAs were prepared from diagnostic paraffin-embedded blocks according to established protocols. Sections were immunostained for CD3, CD4, CD8, CD68, CD34, TIA-1, CD163, FOXP3, PD-1, CD57, CD21, P53 and Ki67. Survival correlates were assessed by Cox regression using SPSS. Results: The median age was 67 y (range 22-94) with 69% being male. 88% had advanced-stage disease with 16% having a high IPI (4/5). 50 (41%) patients received rituximab as part of initial or subsequent therapy. Primary and secondary treatment regimens included: observation (19); single agent alkylators (33); CHOP-like with rituximab (39); CHOP-like without rituximab (32); CVP-like (11); higher intensity regimens (9); fludarabine-based (19); gemcitabine-based (9); bortezimib (4); flavopiridol (2); autologous stem cell transplant (12); allogeneic stem cell transplant (2); radiation (45); and therapeutic splenectomy (6). The median follow up of the living patients was 30 months. The 5-y OS for the group was 21%. FCM median tumor content was high at 84% (range 21-100%) with median CD3, CD4, CD8 and non-tumor CD20 populations of 12%, 7%, 4% and 1%, respectively. Univariate analysis revealed CD8 35% was also adversely associated with OS (p=0.028). Conclusion: While the non-neoplastic cellular infiltrate often constitutes only a minor fraction of the tumor mass in MCL, it appears to significantly influence response to rituximab therapy. Further studies are required to validate this observation prospectively and define the mechanism by which the cytotoxic T-cells exert their influence. Disclosures: Connors: Roche Canada: Research Funding. Gascoyne: Roche Canada, Genentech, Lilly, Millennium: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding.